|
Hyperopia, High
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that βII-tubulin may facilitate cancer growth and metastasis and, to accomplish this, may not need to be in microtubule form.
|
30621030 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
We also concluded that chemotherapy enriched to increase TUBB4B level and/or to stabilize microtubule polymerization might more effectively prevent metastasis in colon cancer development.
|
31375012 |
2019 |
|
Tremor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
However, it cannot be excluded that at the dose used, metoprolol had lost its relative cardio-selectivity and that the reduction in tremor was mediated by competitive antagonism at beta-2 receptor sites in skeletal muscle.
|
7031187 |
1981 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The association of βII expression and its nuclear localization with cancer progression has not previously been addressed.
|
30621030 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We also found that βII appears in the nuclei of otherwise normal cells adjacent to the tumor.
|
30621030 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In contrast, 2BECFP cells have a reduced tumor-take and tumor volume in vivo even though the overexpression of beta-2 was maintained.
|
22127840 |
2012 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
PKC-β knockout mice are insusceptible to CLL transplantations, underscoring the in vivo significance of the PKC-βII-NF-κB signaling pathway in the tumor microenvironment.
|
23328482 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Thus, PKC Beta II is a tumour suppressor in colon cancer and low levels serve as a predictor for poor survival outcome.
|
26989024 |
2016 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Expression of the 185 kd c-erb beta-2 protein product was detected in 3 of 19 (16%) tumours by western blotting and in 5 of 19 (26%) by immunohistochemistry.
|
1347417 |
1992 |
|
Neoplasms
|
0.060 |
PosttranslationalModification
|
group |
BEFREE |
RAR-beta(2) promoter was methylated in 67, 56, and 53% of HNSCC tumors, HNSCC cell lines, and microdissected oral leukoplakia specimens, respectively.
|
15014026 |
2004 |
|
Diabetes Mellitus
|
0.030 |
GeneticVariation
|
group |
BEFREE |
To identify mutations in the NeuroD/BETA2 gene that may predispose patients to develop diabetes, we studied the gene in 50 Japanese subjects with diabetes (4 with type 1 and 46 with type 2) by the polymerase chain reaction (PCR) followed by single-strand conformation polymorphism and sequencing analyses.
|
10334323 |
1999 |
|
Diabetes Mellitus
|
0.030 |
GeneticVariation
|
group |
BEFREE |
A novel mutation, Ser159Pro in the NeuroD1/BETA2 gene contributes to the development of diabetes in a Chinese potential MODY family.
|
17440689 |
2007 |
|
Diabetes Mellitus
|
0.030 |
GeneticVariation
|
group |
BEFREE |
In the present study, we examined mutations in the NeuroD/BETA2 gene for association with either type 1 or 2 diabetes.
|
10905500 |
2000 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that βII-tubulin may facilitate cancer growth and metastasis and, to accomplish this, may not need to be in microtubule form.
|
30621030 |
2019 |
|
Hematologic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Upregulated stromal PKC-βII in biopsies from patients with CLL, acute lymphoblastic leukemia, and mantle cell lymphoma suggests that this pathway may commonly be activated in a variety of hematological malignancies.
|
23328482 |
2013 |
|
Neuropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
There were no significant associations between clinician-reported neuropathy or patient-reported neuropathy and TUBB2, CEP72 or individual MAPT or GSK3B SNPs, however MAPT additive polymorphisms were associated with patient-reported neuropathy and GSK3B additive polymorphisms were associated with clinician reported CIPN.
|
29117336 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that βII-tubulin may facilitate cancer growth and metastasis and, to accomplish this, may not need to be in microtubule form.
|
30621030 |
2019 |